InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (10 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
10
T+90 hit rate
0%
T+90 mean return
-19.1%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by Jacobs Jeffrey W, Directeur Scientifique. Insider active across 1 company, notably Ardelyx, INC.. In total, 14 reports have been logged. Split: 0 buy · 10 sells. Total volume traded: €33k. Activity tracked since 20 May 2021. The latest transaction was disclosed on 22 November 2021 (Cession). Regulator: SEC (Form 4). All data is openly available.
Declarations14 total
5,000 shares@ US$0.97638.9% of flowCommon StockSEC:0001567619-21-021161
5,000 shares@ US$0.97630.0003% mcap8.9% of flowCommon StockSEC:0001567619-21-021161:0
5,000 shares@ US$1.130.0003% mcap10.1% of flowCommon StockSEC:0001567619-21-020591:0
5,000 shares@ US$1.1310.1% of flowCommon StockSEC:0001567619-21-020591
2,166 shares@ US$1.180.0002% mcap4.5% of flowCommon StockSEC:0001567619-21-019728:0
2,166 shares@ US$1.184.5% of flowCommon StockSEC:0001567619-21-019728
741 shares@ US$1.320.0001% mcap1.7% of flowCommon StockSEC:0001567619-21-016283:0
741 shares@ US$1.321.7% of flowCommon StockSEC:0001567619-21-016283
10,000 shares@ US$0.540.0003% mcap9.3% of flowCommon StockSEC:0001567619-21-014510:0
10,000 shares@ US$0.549.3% of flowCommon StockSEC:0001567619-21-014510
7,500 shares@ US$0.546.8% of flowCommon StockSEC:0001567619-21-012329
7,500 shares@ US$0.540.0002% mcap6.8% of flowCommon StockSEC:0001567619-21-012329:0
721 shares@ US$7.08788.6% of flowCommon StockSEC:0001567619-21-010921
721 shares@ US$7.08780.0003% mcap8.6% of flowCommon StockSEC:0001567619-21-010921:0
14 of 14 declarations
About Jacobs Jeffrey W
Jeffrey W. Jacobs is the Chief Scientific Officer at Ardelyx, Inc. He is responsible for leading the company's research and development initiatives. His scientific expertise is essential in guiding Ardelyx's innovative projects, which focus on treatments for gastrointestinal diseases.
